A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2521-2533

  Ungphakorn, Wanchana ^a   Tängdén, Thomas ^a   Sandegren, Linus ^a   Nielsen, Elisabet I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; ERTAPENEM; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN F; PORIN;

ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; GENETIC SELECTION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; SECRETION (PROCESS); TIME FACTOR;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PORINS; SELECTION, GENETIC; TIME FACTORS;

EID: 84996703799     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw205     Document Type: Article

References (40)

1. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
2. Poirel L, Héritier C, Spicq C et al. In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clin Microbiol 2004; 42: 3831-3.
3. Lartigue MF, Poirel L, Poyart C et al. Ertapenem resistance of Escherichia coli. Emerg Infect Dis 2007; 13: 315-7.
4. Tängdén T, Adler M, Cars O et al. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBLproducing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. J Antimicrob Chemother 2013; 68: 1319-26.
5. Zhanel GG, Wiebe R, Dilay L et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027-52.
6. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-44.
7. Majumdar AK, Musson DG, Birk KL et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-11.
8. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19: 261-8.
9. Maglio D, Banevicius MA, Sutherland C et al. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob Agents Chemother 2005; 49: 276-80.
10. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004; 53 Suppl 2: ii23-8.
11. Adler M, Anjum M, Andersson DI et al. Influence of acquired b-lactamases on the evolution of spontaneous carbapenem resistance in Escherichia coli. J Antimicrob Chemother 2013; 68: 51-9.
12. Girlich D, Poirel L, Nordmann P. CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2009; 53: 832-4.
13. Guillon H, Tande D, Mammeri H. Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum b-lactamase AmpC. Antimicrob Agents Chemother 2011; 55: 4443-6.
14. Campion JJ, McNamara PJ, Evans ME. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 209-19.
15. TamVH, Schilling AN, Nikolaou M. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 2005; 55: 699-706.
16. Meagher AK, Forrest A, Dalhoff A et al. Novel pharmacokineticpharmacodynamic model for prediction of outcomes with an extendedrelease formulation of ciprofloxacin. Antimicrob Agents Chemother 2004; 48: 2061-8.
17. Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41: 363-73.
18. Jumbe N, Louie A, Leary R et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112: 275-85.
19. Bulitta JB, Ly NS, Yang JC et al. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 46-56.
20. Bulitta JB, Yang JC, Yohonn L et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010; 54: 2051-62.
21. Mohamed AF, Nielsen EI, Cars O et al. Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother 2012; 56: 179-88.
22. Khan DD, Lagerbäck P, Cao S et al. A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. J Antimicrob Chemother 2015; 70: 3051-60.
23. Sandegren L, Linkevicius M, Lytsy B et al. Transfer of an Escherichia coli ST131 multiresistance cassette has created a Klebsiella pneumoniaespecific plasmid associated with a major nosocomial outbreak. J Antimicrob Chemother 2011; 67: 74-83.
24. Nielsen EI, Viberg A, Löwdin E et al. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother 2007; 51: 128-36.
25. Balaban NQ, Merrin J, Chait R et al. Bacterial persistence as a phenotypic switch. Science 2004; 305: 1622-5.
26. Keren I, Kaldalu N, Spoering A et al. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 2004; 230: 13-8.
27. Tam VH, Ledesma KR, Vo G et al. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother 2008; 52: 3987-93.
28. Beal S, Sheiner LB, Boeckmann A et al. NONMEM User's Guides (1989-2009). Ellicott City, MD: Icon Development Solutions, 2009.
29. Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J 2009; 11: 371-80.
30. Karlsson MO, Holford N. A tutorial on visual predictive checks. In: Abstracts of the Seventeenth Population Approach Group in Europe, Marseille, France, 2008. Abstract 1434.
31. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
32. Dosne AG, Bergstrand M, Karlsson MO. Application of Sampling Importance Resampling to estimate parameter uncertainty distributions. In: Abstracts of the Twenty-second Population Approach Group in Europe, Glasgow, Scotland, 2013. Abstract 2907.
33. Wiskirchen DE, Housman ST, Quintiliani R et al. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy 2013; 33: 266-74.
34. Adler M, Anjum M, Berg OG et al. High fitness costs and instability of gene duplications reduce rates of evolution of new genes by duplicationdivergence mechanisms. Mol Biol Evol 2014; 31: 1526-35.
35. Leavitt A, Chmelnitsky I, Colodner R et al. Ertapenem resistance among extended-spectrum-b-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol 2009; 47: 969-74.
36. Livermore DM, Oakton KJ, Carter MW et al. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent b-lactamases. Antimicrob Agents Chemother 2001; 45: 2831-7.
37. Ludwig E, Konkoly-Thege M, Kuti JL et al. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Int J Antimicrob Agents 2006; 28: 433-8.
38. Dandekar PK, Maglio D, Sutherland CA et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003; 23: 988-91.
39. Falagas ME, Tansarli GS, Ikawa K et al. Clinical outcomes with extended or continuous versus short-termintravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2012; 56: 272-82.
40. Tamma PD, Putcha N, Suh YD et al. Does prolonged b-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 2011; 11: 181.